The KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.

Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.

The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.

The Portnoy Law Firm has initiated an investigation into Verastem, Inc. (NASDAQ: VSTM) for potential securities fraud after the company disclosed serious adverse events in a clinical trial, causing a significant drop in its stock price.

Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk. Find out why VSTM stock is a Buy.

Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ: MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated video modernization with NVIDIA at the ACM Mile-High-Video 2024 conference. DIH Holdings US, Inc. (NASDAQ: DHAI) shares climbed 65.2% to $2.1306. DIH Holding US secured $1.5 million in private placement financing from OrbiMed. ContextLogic Inc. (NASDAQ: WISH) gained 40.2% to $6.31 after the company announced an agreement to sell substantially all of its operating assets and liabilities to Qoo10 for approximately $173 million in cash. SuperCom Ltd. (NASDAQ: SPCB) shares jumped 40% to $0.2570. SuperCom recently disclosed that it has secured a new contract with an established California services provider in the judicial sector. Intuitive Machines, Inc. (NASDAQ: LUNR) shares gained 33.3% to $6.65 after jumping around 32% on Friday. D-Wave Quantum Inc. (NYSE: QBTS) gained 31% to $1.4295. Renalytix Plc (NASDAQ: RNLX) surged 27% to $0.4842. Genasys Inc. (NASDAQ: GNSS) gained 27% to $1.98. Genasys bagged critical infrastructure project to engineer, procure and build emergency warning system for 37 dams across the island of Puerto Rico. Root, Inc. (NASDAQ: ROOT) rose 22.6% to $9.30. Syra Health Corp. (NASDAQ: SYRA) ...

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Verastem (NASDAQ:VSTM) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 1 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Verastem has an average price target of $28.0 with a high of $36.00 and a low of $21.00. Below is a summary of how these ...Full story available on Benzinga.com

An application for Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. Read more here.